Full-Course ECMO Strategy for Moderate-to-Severe ARDS
Establishment and Evaluation of a Full-Course ECMO Management Strategy for Patients With Moderate-to-Severe ARDS
China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates. A key underlying reason is the lack of a standardized full-course management pathway that is applicable to real-world clinical practice in China. This study focuses on the construction and evidence-based evaluation of a precision full-course ECMO management pathway for patients with moderate-to-severe ARDS, aiming to address fragmented care processes and delayed quality improvement.
The study includes three main components. First, multidisciplinary consensus and evidence-based findings will be integrated to develop a standardized management pathway covering the full chain of assessment, initiation, maintenance, weaning, and rehabilitation. Second, a nationwide multicenter real-world study with a before-and-after design will be conducted to systematically evaluate the clinical effectiveness of this pathway in reducing mortality and complications and improving patient outcomes. Third, a closed-loop dynamic optimization system based on "pathway-data-feedback-improvement" will be established. With the support of an intelligent data platform and multidisciplinary review mechanisms, the pathway will be continuously updated and refined.
Through this study, a reproducible, traceable, and evaluable full-course ECMO management strategy is expected to be established. The study will also build a national collaborative research network and support the development of living clinical guidance, promoting the transition of ECMO care in China from experience-based practice toward standardized, homogeneous, and intelligent management, and providing a key technical framework and practical model for improving critical care.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study focuses on the establishment, clinical evaluation, and dynamic optimization of a full-course ECMO management pathway for patients with moderate-to-severe ARDS.
First, a standardized full-course ECMO management pathway will be developed based on evidence-based medicine and multidisciplinary collaboration. The pathway will cover the entire clinical process, including assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, ECMO weaning, rehabilitation, and follow-up. The aim is to standardize key clinical decision points and improve the homogeneity of ECMO care across participating centers.
Second, the clinical effectiveness of the full-course ECMO management pathway will be evaluated through a multicenter, real-world, before-and-after clinical study. Patients treated before implementation of the pathway will serve as the control group, while patients treated after implementation will receive care according to the standardized pathway. The study will systematically assess whether implementation of the pathway improves clinical outcomes in patients with moderate-to-severe ARDS receiving ECMO.
Third, a closed-loop system for pathway implementation and dynamic optimization will be established. This system will follow a "pathway-data-feedback-improvement" model. Based on updated guidelines and evidence generated from this study, key intervention points, process key performance indicators, and quality indicators will be defined. A unified electronic pathway and data dictionary will be used across participating centers. Physicians, respiratory therapists, and nurses will record key parameters and reasons for pathway deviations through an intelligent data platform.
Regular multidisciplinary reviews will be conducted monthly or quarterly to evaluate pathway implementation, identify process barriers, analyze center-level variation, and review the root causes of adverse events. Statistical process control, cumulative sum analysis, and risk-adjusted benchmarking may be used to support quality monitoring and continuous improvement. Based on the accumulated clinical data and evidence, living clinical guidance or practice recommendations will be updated iteratively.
The final goal of this study is to establish a reproducible, traceable, and evaluable full-course ECMO management pathway for patients with moderate-to-severe ARDS, thereby supporting standardized and homogeneous ECMO care across multiple centers.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:yingzi Huang, M.D.
- 電話番号:18271428804
- メール:yz_huang@126.com
研究場所
-
-
-
Beijing、中国
- 募集
- Beijing AnZhen Hospital, Capital Medical University
-
コンタクト:
- Zhongtao Du
-
Changchun、中国
- まだ募集していません
- The Second Hospital of Jilin University
-
Chengdu、中国
- まだ募集していません
- West China Tianfu Hospital, Sichuan University
-
Chenzhou、中国
- まだ募集していません
- The First People's Hospital of Chenzhou
-
Dalian、中国
- 募集
- The Second Affiliated Hospital of Dalian Medical University
-
Fuzhou、中国
- 募集
- Fuzhou University Affiliated Provincial Hospital
-
コンタクト:
- Shang
-
Guangzhou、中国
- 募集
- The First Affiliated Hospital of Guangzhou Medical University
-
コンタクト:
- Yan Wang
-
Hangzhou、中国
- 募集
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
コンタクト:
- Xie
-
Hangzhou、中国
- まだ募集していません
- Affiliated Hangzhou First People's Hospital of Westlake University School of Medicine
-
Ha’erbin、中国
- まだ募集していません
- The First Affiliated Hospital of Harbin Medical University
-
Ha’erbin、中国
- 募集
- The Second Affiliated Hospital of Harbin Medical University
-
コンタクト:
- Hongliang Wang
-
Huai'an、中国
- まだ募集していません
- Huai'an first people's hospital
-
Jinan、中国
- 募集
- Qilu Hospital of Shandong University
-
コンタクト:
- Hao Wang
-
Kunshan、中国
- まだ募集していません
- The First People's Hospital of Kunshan
-
Lanzhou、中国
- まだ募集していません
- The First Hospital of Lanzhou University
-
Lianyungang、中国
- まだ募集していません
- The first people's hospital of Lianyungang
-
Liuzhou、中国
- 募集
- Liuzhou People's Hospital
-
コンタクト:
- Wenfang Jiang
-
Nanjing、中国
- まだ募集していません
- Jiangsu Province Hospital
-
Nanjing、中国
- 募集
- Zhongda Hospital Southeast University
-
コンタクト:
- Xiaojing Wu
- 電話番号:13951876234
- メール:36410257@qq.com
-
Nanjing、中国
- 募集
- Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
-
コンタクト:
- Danjiang Dong
-
Nanning、中国
- まだ募集していません
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Nanning、中国
- まだ募集していません
- The First Affiliated Hospital of Guangxi Medical University
-
Nanning、中国
- まだ募集していません
- The Second Affiliated Hospital of Guangxi Medical University
-
Nantong、中国
- まだ募集していません
- Affiliated Hospital of Nantong University
-
Ningxiang、中国
- まだ募集していません
- General Hospital of Ningxia Medical University
-
Qinghai、中国
- まだ募集していません
- The Affiliated Hospital of Qinghai University
-
Quzhou、中国
- 募集
- Quzhou people's Hospital
-
Sichuan、中国
- 募集
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMS&SPPH, Affiliated Hospital of UESTC)
-
コンタクト:
- Hongli He
-
Suining、中国
- まだ募集していません
- Suining Central Hospital
-
Suzhou、中国
- まだ募集していません
- The First Affiliated Hospital of Soochow University
-
Wuxi、中国
- 募集
- Wuxi People's Hospital
-
コンタクト:
- Hongyang Xu
-
Xi'an、中国
- 募集
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
コンタクト:
- jing Geng
-
Xiamen、中国
- まだ募集していません
- The First Affiliated Hospital of Xiamen University
-
Xinyang、中国
- まだ募集していません
- Xinyang Central Hospital
-
Xuzhou、中国
- まだ募集していません
- The Affiliated Hospital of Xuzhou Medical Universit
-
Yangzhou、中国
- まだ募集していません
- Northern Jiangsu People's Hospital
-
Zhengzhou、中国
- 募集
- Henan Provincial People's Hospital
-
コンタクト:
- Huanzhang Shao
-
Zhengzhou、中国
- まだ募集していません
- The First Affiliated Hospital of Zhengzhou University
-
Zhongshan、中国
- まだ募集していません
- Zhongshan Hospital of Traditional Chinese Medicine
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- 1. Age 18 years or older. 2. Diagnosed with moderate-to-severe acute respiratory distress syndrome according to the global definition of ARDS.
Exclusion Criteria:
- 1. Patients with tracheostomy before screening. 2. Patients who have received lung transplantation or are receiving venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation.
3. Patients with cardiogenic shock requiring venoarterial ECMO or venoarterial-venous ECMO support.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:Pre-Implementation Usual Care
Participants in this arm are patients with moderate-to-severe ARDS who received ECMO before implementation of the standardized full-course ECMO management pathway.
Clinical care will be provided according to usual practice at each participating center, including ECMO initiation, maintenance, complication management, weaning, and rehabilitation based on local protocols and clinician judgment.
|
Usual care refers to ECMO management provided before implementation of the standardized full-course ECMO management pathway.
Clinical decisions are made according to local practice and clinician judgment at each participating center.
|
|
実験的:Post-Implementation ECMO Management Pathway
Participants in this arm are patients with moderate-to-severe ARDS who receive ECMO after implementation of the standardized full-course ECMO management pathway.
Clinical care will follow the pathway covering assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, weaning assessment, rehabilitation, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded.
|
The intervention is a standardized full-course ECMO management pathway for patients with moderate-to-severe ARDS.
The pathway covers assessment of ECMO indications, ECMO initiation, cannulation and anticoagulation strategies, mechanical ventilation management, hemodynamic and fluid management, infection prevention, analgesia and sedation, nutrition and rehabilitation, complication prevention and management, weaning assessment, discharge, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded for quality improvement and subsequent analysis.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
90-Day All-Cause Mortality
時間枠:From ECMO initiation to 90 days after ECMO initiation
|
From ECMO initiation to 90 days after ECMO initiation
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
28-Day All-Cause Mortality
時間枠:28 days after ECMO initiation
|
The proportion of participants who die from any cause within 28 days after ECMO initiation will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
28 days after ECMO initiation
|
|
Successful Liberation From Mechanical Ventilation
時間枠:From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
Successful liberation from mechanical ventilation is defined as survival without reintubation or death within 7 days after extubation in patients without tracheostomy, or survival without reconnection to mechanical ventilation or death within 7 days afte
|
From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
|
ICU Mortality
時間枠:From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during the ICU stay will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
|
ICU Length of Stay
時間枠:From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
ICU length of stay is defined as the number of days from ICU admission to ICU discharge or death.
|
From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at ICU Discharge
時間枠:At ICU discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at ICU discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Hospital Mortality
時間枠:From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during hospitalization will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
|
Hospital Length of Stay
時間枠:From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
Hospital length of stay is defined as the number of days from hospital admission to hospital discharge or death.
|
From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at Hospital Discharge
時間枠:At hospital discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at hospital discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Incidence of ECMO-Related Complications
時間枠:From ECMO initiation to 48 hours after ECMO decannulation
|
The incidence of ECMO-related complications will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
ECMO-related complications include major bleeding, minor bleeding, mechanical or circuit thrombosis, patient-related thrombosis, hospital-acquired infection during ECMO, hemolysis, cannulation-related complications, acute kidney injury, and oxygenator replacement.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Major Bleeding Events
時間枠:From ECMO initiation to 48 hours after ECMO decannulation
|
Major bleeding is defined as bleeding that meets at least one of the following criteria: life-threatening bleeding, including intracranial bleeding, retroperitoneal bleeding, cardiac tamponade, or bleeding leading to hemorrhagic shock; bleeding requiring surgical intervention; or transfusion of at least 2 units of red blood cells within 24 hours due to active bleeding.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Minor Bleeding Events
時間枠:From ECMO initiation to ECMO decannulation
|
Mechanical or circuit thrombosis is defined as thrombus formation observed or diagnosed within the extracorporeal circuit during ECMO support, including thrombosis in the ECMO oxygenator, pump head, tubing, connectors, or other circuit components.
|
From ECMO initiation to ECMO decannulation
|
|
Patient-Related Thrombotic Events
時間枠:From ECMO initiation to 48 hours after ECMO decannulation
|
Patient-related thrombotic events are defined as thrombotic or embolic events occurring within the patient's vascular system and confirmed by clinical findings, imaging, or autopsy.
Events include deep vein thrombosis, pulmonary embolism, and ischemic stroke.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Hospital-Acquired Infection During ECMO
時間枠:From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
Hospital-acquired infection during ECMO is defined as infection occurring more than 24 hours after ECMO initiation and up to 48 hours after ECMO decannulation.
Infection sites include bloodstream infection, respiratory tract infection or ventilator-associated pneumonia, mediastinitis, cannulation-site or surgical-site infection, urinary tract infection, or other documented infection sites.
|
From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
|
Hemolysis During ECMO
時間枠:From ECMO initiation to ECMO decannulation
|
Hemolysis is defined as plasma-free hemoglobin greater than 500 mg/L, equivalent to greater than 50 mg/dL, after ECMO cannulation.
|
From ECMO initiation to ECMO decannulation
|
|
Cannulation-Related Complications
時間枠:From ECMO cannulation to 48 hours after ECMO decannulation
|
Cannulation-related complications include limb ischemia, pseudoaneurysm, arteriovenous fistula, vascular dissection, or other vascular complications related to ECMO cannulation.
Limb ischemia is defined as impaired distal perfusion of the cannulated limb requiring clinical evaluation or intervention.
|
From ECMO cannulation to 48 hours after ECMO decannulation
|
|
Acute Kidney Injury During ECMO
時間枠:From ECMO initiation to ECMO decannulation
|
Acute kidney injury during ECMO will be assessed according to KDIGO criteria and classified as stage 1, stage 2, or stage 3.
The need for continuous renal replacement therapy will also be recorded.
|
From ECMO initiation to ECMO decannulation
|
|
Oxygenator Replacement
時間枠:From ECMO initiation to ECMO decannulation
|
Oxygenator replacement is defined as replacement of the ECMO oxygenator for any reason during ECMO support, including oxygenator thrombosis, gas exchange dysfunction, increased transmembrane pressure, hemolysis, or other clinical indications.
|
From ECMO initiation to ECMO decannulation
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2026ZDSYLL081-P01
- 2026ZD0555505 (その他の助成金/資金番号:National Key R&D Program of China)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。